key: cord-1029969-tzjvq44x authors: Feng, Kuan; Min, Yuan-Qin; Sun, Xiulian; Deng, Fei; Li, Peiqing; Wang, Hualin; Ning, Yun-Jia title: Interactome profiling reveals interaction of SARS-CoV-2 NSP13 with host factor STAT1 to suppress interferon signaling date: 2021-10-23 journal: J Mol Cell Biol DOI: 10.1093/jmcb/mjab068 sha: b2bb02f33a4307ef1b537ec15c8fbcf58951b016 doc_id: 1029969 cord_uid: tzjvq44x nan NSP13 is important in viral replication as a helicase unwinding duplex RNA and a 5′-triphosphatase likely involved in 5′-capping of viral mRNA (Min et al., 2021) . We observed robust inhibition of type I IFN signaling by SARS-CoV-2 NSP13 through reporter gene assays Additionally, time-sensitive preparation of the manuscript precluded visual results (immunoblotting or silver staining) demonstrating effective precipitation of baits and cellular proteins before mass spectrometry (MS) (Gordon et al., 2020) . Thus, further exploration of the viral interactome is worthwhile. To elucidate the mechanism of NSP13-mediated IFN signaling antagonism and further decipher the potential cellular interaction landscape of such an important viral protein, we exploited a high-affinity purification assay (S-pulldown) coupled with quantitative MS to identify the cellular interactome of NSP13 ( Figure 1B ). S-tagged NSP13 expressed in cells was efficiently precipitated, and bands of cellular proteins co-precipitating with NSP13 were also evident ( Figure 1C and D). MS analysis identified 172 cellular proteins as potential NSP13-interacting host factors with high confidence (Supplementary Table S1 and Figure S2A ); 171 were newly identified in this study (C1orf50 was also reported by Gordon et al., 2020) . These proteins might affect NSP13 function or be affected by NSP13. We next validated the interactions of NSP13 with a series of representative host proteins through immunoblotting (Supplementary Figure S3) , further supporting the new interactome. Gene ontology and protein-protein interaction network analyses showed that these host proteins were enriched in several important biological processes and some specific molecular Importantly, an essential component of the IFN-triggered signaling pathway, STAT1 (Najjar and Fagard, 2010), was identified as a potential NSP13-interacting protein (Supplementary Table S1 and Figure S2A -C). Given the central role of STAT1 in IFN signaling cascades (Najjar and Fagard, 2010), we speculated that STAT1 might be the cellular interaction target of NSP13 for IFN signaling counteraction. Immunoblotting indicated that STAT1 indeed co-precipitated with NSP13 ( Figure 1H ). Moreover, reciprocal interaction analysis in the context of SARS-CoV-2 infection confirmed co-precipitation of NSP13 with STAT1 ( Figure 1I ). The NSP13-STAT1 interaction was further demonstrated to be independent of RNA or DNA using a nuclease treatment assay (Mo et al., 2020) before protein-interaction detection (Supplementary Figure S4) . Then, we constructed a series of C-terminal truncations based on NSP13 3D structure to map the interaction domain ( Figure 1J and K). Interestingly, truncated NSP13 with the 2A domain deleted (N442) retained interaction with STAT1, whereas removal of the 1A domain (N259) or further deletions (N150 or N100) abolished NSP13-STAT1 interaction ( Figure 1L ), indicating a necessary role of 1A domain ( Figure 1J ) in NSP13 targeting to STAT1. Furthermore, immunofluorescence assays (IFA) demonstrated that NSP13 expression blocks nuclear accumulation of STAT1 induced by IFN- ( Figure 1M ). Interestingly, NSP13 mutant N259 failed to block STAT1 nuclear translocation, while mutant N442 retained inhibitory ability against STAT1 nuclear accumulation (Supplementary Figure S5 ), in line with their interactions with STAT1 ( Figure 1L ). IFN--triggered STAT1 phosphorylation, a prerequisite for STAT1 activation and efficient nuclear translocation, was noticeably reduced by NSP13 ( Figure 1N ). Moreover, inhibition of IFN--stimulated STAT1 activation by NSP13 was comparable to or stronger than that by SOCS1 (Supplementary Figure S6A) , a well-known cellular negative regulator of Janus kinase (Najjar and Fagard, 2010). These consistent observations corroborate that NSP13 suppresses type I IFN signaling by interacting with STAT1 and hence impairing the host protein's actions. As STAT1 is an indispensable signaling molecule shared by all type I, II, and III IFN signaling cascades, we considered that NSP13 might antagonize type II and III IFN signaling as well. Indeed, NSP13 expression significantly inhibited both IFN- and IFN-induced reporter activation ( Figure 1O and P) and antiviral ISG expression (Supplementary Figure S1B and C). Furthermore, STAT1 phosphorylation triggered by type II and III IFNs was also suppressed by NSP13 ( Figure 1Q and R; Supplementary Figure S6B and C). Together, these data suggest that NSP13 targets STAT1 through interaction requiring the NSP13 1A domain, thus interfering with STAT1 actions. The interference ultimately inhibits type I, II, and III IFN signaling cascades that orchestrate complex host immune responses upon viral infection. In summary, we uncovered a new interactome of the critical viral protein NSP13, revealing important aspects of SARS-CoV-2 biology as well as potential druggable targets and targeting drugs at the interface of virus-host interactions. We further demonstrated that nucleic acid-independent interaction of NSP13 with STAT1 involves NSP13 domain 1A and results in inhibition of type I, II, and III IFN-elicited STAT1 actions. Given the IFN-antagonistic and hence potential virulence-associated activities of NSP13, future studies of specific NSP13 mutant viruses (e.g. those constructed by reverse genetics) will further elucidate the biological significance of NSP13 targeting of STAT1 or other host factors and help inform the design of attenuated vaccines. Our findings unravel the cellular interaction target and mechanism for NSP13 blockade of IFN signaling and provide new insights into virus-host interactions from molecular and proteomic perspectives, which benefit not only better understanding of SARS-CoV-2 infection but also further development of antiviral therapies. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 instructions. For WB analysis, protein samples separated by SDS-PAGE were 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 protein-protein association networks with increased coverage, supporting functional 234 discovery in genome-wide experimental datasets. Nucleic Acids Res 47:D607-D613. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Imbalanced host response to SARS-CoV-2 drives development of COVID-19 A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Hypoxia in COVID-19: sign of severity or cause for poor outcomes Activation and evasion of type I interferon responses by SARS-CoV-2 Interferon deficiency can lead to severe COVID Immune evasion of SARS-CoV-2 from interferon antiviral system Host restriction of emerging high-pathogenic bunyaviruses via MOV10 by targeting viral nucleoprotein and blocking ribonucleoprotein assembly Viral suppression of innate immunity via spatial isolation of TBK1/IKKepsilon 164 from mitochondrial antiviral platform Disruption of type I interferon signaling by the nonstructural protein of severe fever with 167 thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into inclusion bodies Ebola virus mucin-like glycoprotein (Emuc) induces remarkable acute 171 inflammation and tissue injury: evidence for Emuc pathogenicity in vivo Heartland virus antagonizes type I and 174 III interferon antiviral signaling by inhibiting phosphorylation and nuclear translocation of 175 STAT2 and STAT1 Interferon-gamma-Directed Inhibition of a Novel High-Pathogenic Phlebovirus 178 and Viral Antagonism of the Antiviral Signaling by Targeting STAT1 Nonstructural Protein of Guertu Virus Disrupts Host Defenses by Blocking Antiviral Interferon 181 Induction and Action Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate antiviral immune 184 response LSm14A is a processing body-associated sensor of viral nucleic acids that initiates cellular 187 antiviral response in the early phase of viral infection 190 WDR5 is essential for assembly of the VISA-associated signaling complex and virus-triggered 191 IRF3 and NF-kappaB activation The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor 194 activation Phlebovirus and Viral Antagonism of the Antiviral Signaling by Targeting STAT1 Disruption of type I interferon signaling by the nonstructural protein of severe fever with 201 thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into inclusion bodies Host restriction of emerging 204 high-pathogenic bunyaviruses via MOV10 by targeting viral nucleoprotein and blocking 205 ribonucleoprotein assembly Heartland virus NSs 207 protein disrupts host defenses by blocking the TBK1 kinase-IRF3 transcription factor 208 interaction and signaling required for interferon induction A RIG-I-like receptor directs antiviral 210 responses to a bunyavirus and is antagonized by virus-induced blockade of TRIM25-mediated 211 ubiquitination Comprehensive analysis of phosphorylation sites in Tensin1 reveals regulation by p38MAPK Heartland virus NSs protein 216 disrupts host defenses by blocking the TBK1 kinase-IRF3 transcription factor interaction and 217 signaling required for interferon induction Linear ubiquitination of NEMO negatively regulates the interferon 221 antiviral response through disruption of the MAVS-TRAF3 complex Performance Evaluation of the Q Exactive HF-X for Shotgun Proteomics Accurate 227 proteome-wide label-free quantification by delayed normalization and maximal peptide ratio 228 extraction, termed MaxLFQ STRING v11